1. Home
  2. ITRG vs ADCT Comparison

ITRG vs ADCT Comparison

Compare ITRG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra Resources Corp.

ITRG

Integra Resources Corp.

HOLD

Current Price

$3.50

Market Cap

482.5M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$4.31

Market Cap

454.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ITRG
ADCT
Founded
1997
2011
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
482.5M
454.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ITRG
ADCT
Price
$3.50
$4.31
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$4.00
$7.60
AVG Volume (30 Days)
2.2M
743.6K
Earning Date
11-12-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.08
N/A
Revenue
$219,125,000.00
$75,209,000.00
Revenue This Year
$709.65
$11.78
Revenue Next Year
$36.86
$4.83
P/E Ratio
$45.52
N/A
Revenue Growth
N/A
6.35
52 Week Low
$0.79
$1.05
52 Week High
$3.52
$4.80

Technical Indicators

Market Signals
Indicator
ITRG
ADCT
Relative Strength Index (RSI) 66.21 56.64
Support Level $2.73 $3.95
Resistance Level $3.12 $4.45
Average True Range (ATR) 0.23 0.26
MACD 0.05 0.03
Stochastic Oscillator 96.83 76.72

Price Performance

Historical Comparison
ITRG
ADCT

About ITRG Integra Resources Corp.

Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: